Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn’s disease in children

Arie Levine, Efrat Broide, Michal Stein, Yoram Bujanover, Zvi Weizman, Gabriel Dinari, Avi Pacht, David Branski, Ilan Zahavi

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Objectives: Oral budesonide has been found to be efficacious for mild to moderate Crohn’s disease in adults, with equal improvement rates for budesonide and prednisone. We report the results of a retrospective study of budesonide treatment in mild to moderate Crohn’s disease in children. Study design: Charts of patients treated with budesonide (n = 62) with a pediatric Crohn’s Disease Activity Index of 12.5 to 40 were compared with a cohort of 58 age-matched patients treated with prednisone. Results: Among children treated with budesonide, 48% had remission compared with 77% of the children treated with prednisone (P =.001). Among patients who had failed previous medical therapy with mesalamine, 59% had remission with budesonide (9 mg/day). Remission with prednisone occurred in 73% of children who failed to achieve remission with budesonide. Patients responding to budesonide had significantly milder disease compared with nonresponders who had remission while taking prednisone. Conclusions: Budesonide is useful in mild to moderate Crohn’s disease in children. It is more effective than mesalamine and antibiotics but less effective than prednisone. Budesonide should be considered for first-line therapy in mild to moderate Crohn’s disease.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalJournal of Pediatrics
Volume140
Issue number1
DOIs
StatePublished - 1 Jan 2002
Externally publishedYes

Fingerprint

Dive into the research topics of 'Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn’s disease in children'. Together they form a unique fingerprint.

Cite this